Skip to main content
. 2024 May 15;14:1395978. doi: 10.3389/fonc.2024.1395978

Figure 4.

Figure 4

A fold-change above the median of 0.95 for IL-15 [(A), Stage III]; 1.00 for TRAIL [(B), Stage III]; and 1.02 for IL-16 [(C), Stage IV] was significantly associated with improved PFS.